Skip to content

General practice endorsement in the Bowel Cancer Screening Programme

General practice endorsement in the Bowel Cancer Screening Programme: the ASCEND2 project

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN11660314
Enrollment
97616
Registered
2015-07-16
Start date
2016-02-01
Completion date
Unknown
Last updated
2022-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer/bowel cancer Cancer

Interventions

ASCEND2 will compare the effectiveness of using a general practice endorsement banner on kit invitation letters sent as part of the BCSP, against the standard letter currently sent out by the BCSP. In

Sponsors

Imperial College London (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Men and women aged between 60-74 years who have a registered GP

Exclusion criteria

Exclusion criteria: 1. We will only be able to randomise eligible people to receive this intervention if they are registered with practices that agreed to endorse the BCSP during the preceding trial, ASCEND. 2. Invited subjects may contact their BCSP hub and opt-out of the current screening episode and others for reasons of informed choice or poor health and they can choose to be ceased from the screening programme. 'Ceased' subjects, if ceased prior to their screening due date will not be invited to be screened.

Design outcomes

Primary

MeasureTime frame
Proportion of people in each Index of Multiple Deprivation (IMD) quintile returning an adequate faecal occult blood test (FOBt) within 18 weeks of being sent their initial invitation letter. An adequate FOBt in this study is defined as reaching a definitive FOBt outcome of either a 'Normal' (no further clinical investigation is required) or 'Abnormal' (referral for prospective colonoscopy).

Secondary

MeasureTime frame
1. Time taken to return FOBt by IMD quintile 2. Proportion of spoilt kits and their relationship to IMD quintile 3. Proportion of non-delivered kits by IMD quintile 4. Incremental cost per screening invitation 5. Incremental cost per screening invitation, both by IMD quintile and overall 6. All of the above outcomes analysed using other SE variables

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026